Results from an ongoing Phase 2 clinical trial suggest that pomalidomide (Pomalyst) in combination with dexamethasone (Decadron) is effective and well-tolerated in patients who are resistant (refractory) to previous myeloma treatment with both Revlimid (lenalidomide) and Velcade (bortezomib). The findings were presented by Dr. Martha Lacy of the Mayo Clinic at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Saturday.

“We found the pomalidomide-dexamethasone regimen has significant activity in Revlimid- and Velcade-refractory myeloma,” …

Yesterday -- Saturday, June 5 -- was the sec­ond day of the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago.  It was a busy day in terms of re­search posters and pre­sen­ta­tions re­lated to mul­ti­ple myeloma.  As a re­­sult, there is a lot of ground to cover in this up­date.

Almost 40 myeloma-related posters were up for meeting attendees to view during the daytime poster session on "lymphoma and plasma cell disorders."  Among those 40-or-so posters, six con­cerned re­search done by …

Friday, June 4, was the first day of this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Most of the big multiple myeloma news of the day came out of a poster session in the afternoon.

At "poster sessions," researchers present a poster-sized summary of their research in a small, 2 meter by 1 meter cubicle. Researchers and physicians mill about, taking pictures of the posters with their cell phone cameras or taking notes. Sometimes one or more …

Preliminary results from an ongoing Phase 1b clinical trial suggest that carfilzomib (Kyprolis) in com­bi­na­tion with Revlimid (lena­lido­mide) and low-dose dexamethasone (Decadron) is well-tolerated over extended periods of ther­apy in patients who have re­lapsed or are resistant (refractory) to pre­vi­ous myeloma treat­ment.

The findings were presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Carfilzomib is a new ther­apy being developed by Onyx Pharmaceuticals and studied for the treat­ment of patients with re­lapsed …

After my initial multiple myeloma diagnosis in April 2007, I was immediately rushed to a radiation oncologist for treatment. My myeloma had done a real number on my bones. I had lesions in my legs, hips, and ribs, but the worst, most dangerous lesions were in and around my vertebrae.

Extensive radiation helped shrink the lesions. A corticosteroid, dexamethasone, helped with pain and inflammation. However, the combination left me feeling sick and dizzy—a classic case of vertigo.

You …

The Myeloma Beacon is pleased to announce the introduction of German-language translations of select articles on the Beacon website.

The translations are the result of a partnership with the Multiple Myeloma and Plasmacytoma Working Group (APMM), the largest multiple myeloma patient organization in Germany.

“I am extremely pleased that we will be able to offer these translations to our German-speaking readers,” said Maike Haehle, an associate publisher of The Myeloma Beacon and a native German.

Articles available in German …

Hello! My name is Sean Murray. As a myeloma patient marching lockstep alongside you into the daily battle, I am grateful to The Myeloma Beacon for allowing me to share some of my thoughts, experiences, musings, and ‘a-musings’ with you via this new monthly column.

My aim in joining The Myeloma Beacon’s efforts is to offer a patient’s perspective on this extraordinary journey upon which we have embarked.

Perhaps there is something that I have learned along the way that …